| NCT07123727 | A Study to Examine Anktiva for the Treatment of COVID-19. | RECRUITING | PHASE2 | 2025-09 | 2026-07 | 2026-07 |
| NCT06745908 | ResQ201A: Clinical Trial Of N-803 Plus TISLELIZUMAB And DOCETAXEL Versus DOCETAXEL Monotherapy In Participants With Advanced Or Metastatic Non-Small Cell Lung Cancer | RECRUITING | PHASE3 | 2025-09 | 2029-01 | 2028-09 |
| NCT07125872 | Open Label, Phase 2 Study of CD19t-haNK and N-803 in Combination With Rituximab in Participants With Relapsed/ Refractory B-cell Non- Hodgkin Lymphoma. | NOT_YET_RECRUITING | PHASE2 | 2025-08-19 | 2028-05-25 | 2027-05-25 |
| NCT07108036 | A Study to Assess Anktiva in Patients With Long Covid-19. | NOT_YET_RECRUITING | PHASE2 | 2025-08 | 2026-08 | 2026-08 |
| NCT06765954 | Immunotherapy With N 803, ETBX-071, and M-CENK in Combination With Radiation for Participants With High-Risk Prostate Cancer. | NOT_YET_RECRUITING | PHASE2 | 2025-06-01 | 2031-06-30 | 2031-01-31 |
| NCT06765902 | Immunotherapy Before and After Surgery | NOT_YET_RECRUITING | PHASE2 | 2025-05-15 | 2031-06-30 | 2031-01-31 |
| NCT06829823 | Clinical Trial of Ablation Therapy in Participants With Intermediate-Risk Non-Muscle Invasive Papillary Bladder Cancer | NOT_YET_RECRUITING | PHASE2 | 2025-05-01 | 2029-05-01 | 2026-05-01 |
| NCT06800963 | ResQ133A-NMIBC: Intravesical Recombinant Mycobacterium (rMBCG) in Participants With NMIBC Eligible to Receive Intravesical Tice BCG | NOT_YET_RECRUITING | PHASE1, PHASE2 | 2025-05 | 2028-02 | 2028-02 |
| NCT06710288 | A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian Cancer | RECRUITING | PHASE2 | 2024-11-06 | 2027-05 | 2027-05 |
| NCT05618925 | Study for Subjects With Relapsed/Refractory Non- Hodgkin Lymphoma | RECRUITING | PHASE1 | 2024-11-01 | 2027-03-15 | 2026-03-15 |
| NCT06334991 | Study for Subjects with Relapsed/Refractory Non-Hodgkin Lymphoma | RECRUITING | PHASE1 | 2024-08-23 | 2027-03-30 | 2026-03-30 |
| NCT06061809 | N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma | ACTIVE_NOT_RECRUITING | PHASE2 | 2024-08-07 | 2030-12-31 | 2029-12-31 |
| NCT05976828 | IBRX-042 In Participants With HPV-Associated Tumors | RECRUITING | PHASE1 | 2024-06-14 | 2033-08-14 | 2025-09-02 |
| NCT06040918 | Single Center Study Of N-803 Stimulation On Expansion, Enrichment, Proliferation Of Natural Killer Cells Collected By Apheresis | COMPLETED | PHASE1 | 2023-10-04 | 2024-09-03 | 2024-09-03 |
| NCT05304936 | HCW9218 for Advanced Pancreatic Cancer | ACTIVE_NOT_RECRUITING | PHASE1, PHASE2 | 2022-10-17 | 2025-02-01 | 2025-01-01 |
| NCT05370040 | THEMBA II T-Cell Vaccine: Vaccination With saRNA COVID-19 Vaccines | TERMINATED | PHASE1, PHASE2 | 2022-05-05 | 2024-03-11 | 2024-03-11 |
| NCT04845191 | COVID-19 Subcutaneously and Orally Administered Supplemental Vaccine Boost to Enhance T Cell Protection in Those Who Have Already Received EUA S-Based Vaccines | WITHDRAWN | PHASE1, PHASE2 | 2021-12 | 2021-12-14 | 2021-12 |
| NCT04843722 | COVID-19 Supplemental Vaccine Boost to Enhance T Cell Protection in Those Who Have Already Received EUA S-Based Vaccines | WITHDRAWN | PHASE1, PHASE2 | 2021-12 | 2021-12-14 | 2021-12 |
| NCT04927884 | A Study of Sacituzumab With Chemoimmunotherapy to Treat Advanced Triple-Negative Breast Cancer After Prior Therapies | TERMINATED | PHASE1, PHASE2 | 2021-09-08 | 2022-12-12 | 2022-09-13 |
| NCT04898543 | QUILT-3.076: Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid Tumors | ACTIVE_NOT_RECRUITING | PHASE1 | 2021-06-21 | 2025-05-31 | 2025-05-31 |
| NCT04710303 | COVID-19 Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenoviral Platform in Healthy South African Adults | COMPLETED | PHASE1 | 2021-03-02 | 2022-08-02 | 2022-08-02 |
| NCT04732468 | COVID-19 Oral and Subcutaneous Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenovirus Platform in Healthy Volunteers in USA | TERMINATED | PHASE1 | 2021-02-24 | 2023-01-09 | 2022-07-11 |
| NCT06022224 | A 2nd Generation E1/E2B/E3-Deleted Adenoviral COVID-19 Vaccine: The TCELL VACCINE TRIAL | TERMINATED | PHASE2, PHASE3 | 2020-12-09 | 2023-07-19 | 2022-06-23 |
| NCT04591717 | COVID-19 Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenoviral-COVID-19 in Normal Healthy Volunteers | COMPLETED | PHASE1 | 2020-10-19 | 2023-01-18 | 2022-04-20 |
| NCT04397796 | Study of the Safety of Therapeutic Tx With Immunomodulatory MSC in Adults With COVID-19 Infection Requiring Mechanical Ventilation | TERMINATED | PHASE1 | 2020-08-03 | 2020-09-06 | 2020-09-06 |
| NCT04385849 | Study of the Safety of Therapeutic Treatment With an Immunomodulatory Agent (N-803) in Adults With COVID-19 | TERMINATED | PHASE1 | 2020-07-22 | 2020-07-25 | 2020-07-25 |
| NCT04390399 | Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer | ACTIVE_NOT_RECRUITING | PHASE2 | 2020-07-21 | 2025-10-31 | 2025-10-31 |
| NCT03853317 | QUILT-3.063: A Study of N-803, haNK and Avelumab in Patients With Merkel Cell Carcinoma That Has Progressed After Checkpoint Therapy | TERMINATED | PHASE2 | 2020-02-19 | 2022-09-19 | 2021-09-29 |
| NCT04052061 | QUILT-3.061: CD19 t-haNK in Subjects With Diffuse Large B-Cell Lymphoma | WITHDRAWN | PHASE1 | 2019-09-16 | 2022-08-19 | 2021-09-18 |
| NCT04050709 | QUILT-3.064: PD-L1 t-haNK In Subjects With Locally Advanced Or Metastatic Solid Cancers | ACTIVE_NOT_RECRUITING | PHASE1 | 2019-07-18 | 2024-12-30 | 2024-10-31 |
| NCT03228667 | QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors | ACTIVE_NOT_RECRUITING | PHASE2 | 2018-12-11 | 2030-12-31 | 2029-08-31 |
| NCT03755167 | A Follow up Study to Protocol 101/2 - Continued Treatment by IPL344 IV | SUSPENDED | PHASE2 | 2018-12-09 | 2027-02 | 2027-01 |
| NCT03563157 | QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine | TERMINATED | PHASE1, PHASE2 | 2018-09-28 | 2019-08-21 | 2019-04-21 |
| NCT03554109 | QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) Vaccine | WITHDRAWN | PHASE2 | 2018-09 | 2022-02-09 | 2020-06 |
| NCT03647423 | QUILT-3.091 NANT Chordoma Vaccine vs Radiation in Subjects With Unresectable Chordoma. | WITHDRAWN | PHASE1, PHASE2 | 2018-08-31 | 2021-12-28 | 2020-08-31 |
| NCT03652805 | A Study of IPL344 in the Treatment of ALS Patients | SUSPENDED | PHASE1, PHASE2 | 2018-08-01 | 2026-02 | 2026-01 |
| NCT03563144 | QUILT-3.088: NANT Pancreatic Cancer Vaccine | WITHDRAWN | PHASE2 | 2018-08 | 2022-02-09 | 2019-12-30 |
| NCT03169777 | QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC | WITHDRAWN | PHASE1, PHASE2 | 2018-08 | 2021-12-28 | 2019-01 |
| NCT03586869 | QUILT-3.080: NANT Pancreatic Cancer Vaccine | TERMINATED | PHASE1, PHASE2 | 2018-07-17 | 2019-08-01 | 2019-04-17 |
| NCT03574649 | QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer | WITHDRAWN | PHASE2 | 2018-06 | 2018-08-22 | 2018-08 |
| NCT03563170 | QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine | WITHDRAWN | PHASE1, PHASE2 | 2018-05-25 | 2019-08-23 | 2019-08-23 |
| NCT03520686 | Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | PHASE3 | 2018-05-18 | 2026-04-01 | 2025-10-01 |
| NCT03387085 | QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy. | TERMINATED | PHASE1, PHASE2 | 2018-03-19 | 2024-01-16 | 2020-09-11 |
| NCT03169738 | QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors | WITHDRAWN | PHASE1, PHASE2 | 2018-02 | 2021-12-28 | 2019-01 |
| NCT03387111 | QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have Progressed | TERMINATED | PHASE1, PHASE2 | 2018-01-09 | 2021-01-11 | 2019-04-17 |
| NCT03387098 | QUILT-3.070:Pancreatic Cancer Vaccine: Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy | TERMINATED | PHASE1, PHASE2 | 2017-12-28 | 2019-01-15 | 2018-09-12 |
| NCT03197584 | QUILT-3.051: NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects With Epithelial Ovarian Cancer Who Have Progressed on or After Standard-of-care (SoC) Therapy | WITHDRAWN | PHASE1, PHASE2 | 2017-12 | 2021-12-28 | 2019-02 |
| NCT03169790 | QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHL | WITHDRAWN | PHASE1, PHASE2 | 2017-12 | 2021-12-23 | 2019-01 |
| NCT03197571 | QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy | WITHDRAWN | PHASE1, PHASE2 | 2017-12 | 2021-12-28 | 2019-01 |
| NCT03169764 | QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy | WITHDRAWN | PHASE1, PHASE2 | 2017-12 | 2021-12-28 | 2019-01 |
| NCT03167177 | QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 Therapy | WITHDRAWN | PHASE1, PHASE2 | 2017-12 | 2021-12-28 | 2019-01 |
| NCT03175666 | QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based Chemotherapy | WITHDRAWN | PHASE1, PHASE2 | 2017-12 | 2021-12-28 | 2019-01 |
| NCT03167164 | QUILT-3.045: NANT Merkel Cell Carcinoma (MCC) Vaccine: Combination Immunotherapy in Subjects With MCC Who Have Progressed on or After PD-L1 Therapy | WITHDRAWN | PHASE1, PHASE2 | 2017-12 | 2021-12-28 | 2019-01 |
| NCT03329248 | QUILT-3.060: NANT Pancreatic Cancer Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy | TERMINATED | PHASE1, PHASE2 | 2017-11-06 | 2019-11-01 | 2018-08-13 |
| NCT03136406 | QUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy | TERMINATED | PHASE1, PHASE2 | 2017-08-11 | 2019-11-01 | 2017-11-22 |
| NCT03027128 | QUILT-3.028: Study of haNK™ for Infusion in Subjects With Metastatic or Locally Advanced Solid Tumors | COMPLETED | PHASE1 | 2017-08-02 | 2019-05-06 | 2019-05-06 |
| NCT03022825 | QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer | ACTIVE_NOT_RECRUITING | PHASE2, PHASE3 | 2017-06-02 | 2029-03-01 | 2024-10-01 |
| NCT02465957 | QUILT-3.009: Patients With Stage III (IIIB) or Stage (IV) Merkel Cell Carcinoma (MCC) | TERMINATED | PHASE2 | 2015-09-24 | 2018-03-19 | 2018-03-19 |
| NCT02200757 | Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects With Metastatic Small Cell Lung Cancer | COMPLETED | PHASE2 | 2015-04-20 | 2017-05-15 | 2017-05-15 |
| NCT02235701 | Study to Investigate the Safety and Activity of Aldoxorubicin Plus Ifosfamide/Mesna in Subjects With Metastatic Soft Tissue Sarcoma | COMPLETED | PHASE1, PHASE2 | 2014-09-02 | 2018-05-01 | 2018-05-01 |
| NCT02235688 | Study to Investigate the Safety and Activity of Aldoxorubicin Plus Gemcitabine in Subjects With Metastatic Solid Tumors | COMPLETED | PHASE1 | 2014-08 | 2017-01 | 2017-01 |
| NCT02138734 | A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer | RECRUITING | PHASE1, PHASE2 | 2014-07-21 | 2038-12 | 2028-12 |
| NCT00900809 | QUILT-3.018: Neukoplast™ (NK-92) for the Treatment of Refractory or Relapsed Acute Myeloid Leukemia | COMPLETED | PHASE1 | 2014-05-12 | 2015-06-02 | 2015-06-02 |
| NCT02029430 | A Study to Investigate ALDOXORUBICIN in HIV-infected Subjects With Kaposi's Sarcoma | COMPLETED | PHASE2 | 2014-04-03 | 2016-04-25 | 2016-04-25 |
| NCT02014844 | Phase 2 Study to Investigate the Efficacy and Safety of Aldoxorubicin in Subjects With Glioblastoma | COMPLETED | PHASE2 | 2014-03 | 2016-12 | 2016-12 |
| NCT02049905 | Phase 3 Study to Treat Patients With Soft Tissue Sarcomas | COMPLETED | PHASE3 | 2014-01 | 2017-05 | 2017-05 |
| NCT01706835 | Study to Investigate the Pharmacolkinetics of Aldoxorubicin (INNO-206;DOXO-EMCH) Administered as a 30 Minute Infusion Every 3 Weeks in Subjects With Advanced Solid Tumors | COMPLETED | PHASE1 | 2012-10 | 2014-12 | 2014-12 |
| NCT01673438 | Phase 1b Study to Investigate the Safety and Maximum Tolerated Dose of Aldoxorubicin (INNO-206) Plus Doxorubicin HCL in Subjects With Advanced Solid Tumors | COMPLETED | PHASE1 | 2012-07 | 2014-04 | 2014-04 |
| NCT01580397 | Pilot Phase 2 Study to Investigate the Preliminary Efficacy and Safety of INNO-206 in Advanced Pancreatic Cancer | COMPLETED | PHASE2 | 2012-05-16 | 2013-07-02 | 2013-05-13 |
| NCT01514188 | Preliminary Efficacy and Safety of INNO-206 Compared to Doxorubicin in Advanced Soft Tissue Sarcoma | COMPLETED | PHASE2 | 2012-01-11 | 2014-12-15 | 2014-04-09 |
| NCT01337505 | Safety and Maximum Tolerated Dose (MTD) Study of INNO-206 in Subjects With Advanced Solid Tumors | COMPLETED | PHASE1 | 2011-04 | 2012-12 | 2012-09 |